Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 41-47

  Kolnagou, Annita ^a   Economides, Charalambos ^a   Eracleous, Eleni ^a   Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Chelation protocols; Chelation therapy; Deferiprone (L1); Deferoxamine (DFO); Iron overload; Magnetic resonance imaging (MRI) T2*; Serum ferritin; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; CHELATION THERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON STORAGE; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; THALASSEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; CHELATION THERAPY; CLINICAL PROTOCOLS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; PYRIDONES; THALASSEMIA;

EID: 39349096186     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701727085     Document Type: Conference Paper

References (10)

1. Kontoghiorghes GJ. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. Indian J Paediatr 1993; 60(4):485-507.
2. Telfer P, Coen PG, Christou S, Hadjigabriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006; 91(9):1187-1192.
3. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220):2051-2052.
4. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin 2006;30(2):239-249.
5. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332):516-520.
6. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassaemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6):392-397.
7. Kolnagou A, Fessas Ch, Papatryphonas A, Economides Ch, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. Br J Haematol 2004; 127(3):360-361.
8. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2):219-227.
9. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem 2005; 12(23):2663-2681.
10. Mavrogeni SI, Gotsis ED, Markussis V, Tsekos N, Politis C, Vretou E, Kremastinos D. T2 relaxation time study of iron overload in β-thalassemia. MAGMA 1998; 6(1):7-12.